Results 61 to 70 of about 46,300 (164)

Antihypertensive Effect of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists

Cardiology Discovery
An increasing body of evidence shows that new antidiabetic drugs—particularly sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists—have a beneficial effect on cardiovascular outcome.
Marijana Tadic, Cesare Cuspidi
doaj   +1 more source

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Cardiovascular Diabetology, 2018
Background Incretin-based therapies including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) receptor agonists are novel medications for type 2 diabetes management.
Ghadeer K. Dawwas, Steven M. Smith, Haesuk Park   +2 more
doaj   +1 more source

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes [PDF]

, 2016
Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. Methods In this double-blind trial, we randomly assigned patients with type 2 diabetes
Bergenstal, RM, Brown-Frandsen, K, Buse, JB, Daniels, GH, Kristensen, P, LEADER Steering Committee on behalf of the LEADER Trial Investigators, Mann, JF, Marso, SP, Nauck, MA, Nissen, SE, Pocock, S, Poulter, NR, Ravn, LS, Steinberg, WM, Stockner, M, Zinman, B   +15 more
core   +1 more source

Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials

Obesity Pillars
Aim: Obesity is a global epidemic. The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity. Clinical
Haoyang Guo, Juan Yang, Jihan Huang, Ling Xu, Yinghua Lv, Yexuan Wang, Jiyuan Ren, Yulin Feng, Qingshan Zheng, Lujin Li   +9 more
doaj   +1 more source

Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies

International Journal of General Medicine, 2013
John Gerich Department of Medicine, Endocrine/Metabolism Division, University of Rochester School of Medicine, Rochester, NY, USA Abstract: Postprandial plasma glucose concentrations are an important contributor to glycemic control.
Gerich J
doaj  

Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus [PDF]

Pharmacia
In recent years, incretin mimetics have become an important part of type 2 diabetes mellitus therapy. The aim of this study is to evaluate the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists.
Lora Petrova, Kalina Andreevska, Iva Parvova, Valentina Petkova   +3 more
doaj   +3 more sources

Incretin-based therapy for the treatment of bone fragility in diabetes mellitus [PDF]

, 2018
Bone fractures are common comorbidities of type 2 diabetes mellitus (T2DM). Bone fracture incidence seems to develop due to increased risk of falls, poor bone quality and/or anti-diabetic medications.
B. Bouvard, B. Gobron, D. Chappard, G. Mabilleau   +3 more
core   +2 more sources

Mono-ADP-ribosyltransferase as a Potential Pharmacological Drug Target in the GLP-1 Based Therapy of Obesity and Diabetes Mellitus Type 2

Acta Chimica Slovenica, 2013
Glucagon-like peptide-1 (GLP-1) based therapy is well established for treating diabetes mellitus type 2. Moreover, GLP-1 receptor agonists influence weight loss, and have potential for treating obesity.
Aljoša Bavec
doaj  

Integrating the inputs that shape pancreatic islet hormone release. [PDF]

, 2019
The pancreatic islet is a complex mini organ composed of a variety of endocrine cells and their support cells, which together tightly control blood glucose homeostasis.
Huising, Mark O, Noguchi, Glyn M
core  

A single extracellular amino acid in Free Fatty Acid Receptor 2 defines antagonist species selectivity and G protein selection bias [PDF]

, 2017
Free Fatty Acid Receptor 2 is a GPCR activated by short chain fatty acids produced in high levels in the lower gut by microbial fermentation of non-digestible carbohydrates.
Aoki, Junken, Bolognini, Daniele, Hansen, Anders Højgaard, Hudson, Brian D., Inoue, Asuka, Kawakami, Kouki, Kishi, Takayuki, Milligan, Graeme, Sergeev, Eugenia, Ulven, Trond   +9 more
core   +3 more sources